8 completed, 5 not yet recruiting, 5 recruiting, 2 active not recruiting. 3 Not applicable, 3 Phase 3, 3 Phase 4, 1 Phase 1, 1 Phase 2.
Follow Community Acquired Pneumonia (CAP): new trials by email Literature Review of Community Acquired Pneumonia (CAP) trials Research Report on Community Acquired Pneumonia (CAP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily - Community Acquired Pneumonia (CAP) | Phase 4 | Not yet recruiting | University of Maryland, Baltimore | 900 | 2026-09-01 | 2026-09-14 |
| Effect of tNGS on CAP Patients With Initial Treatment Failure Targeted next-generation sequencing, Conventional microbiological testing, Follow-up at Day 30 - Community Acquired Pneumonia (CAP) | Not applicable | Not yet recruiting | Capital Medical University | 524 | 2026-04-10 | 2026-03-16 |
| Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP) | Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 168 | 2026-04-08 | 2026-05-11 |
| Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP) Methylprednisolone (drug), hydrocortisone - Community Acquired Pneumonia (CAP) | Phase 4 | Recruiting | Copenhagen Respiratory Research | 1600 | 2026-03-10 | 2026-03-18 |
| OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis OPT101, Placebo - Sepsis, Community Acquired Pneumonia (CAP) | Phase 1 | Not yet recruiting | Op-T LLC | 26 | 2025-12-01 | 2025-09-15 |
| Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP) Immediate Antibiotic Prescribing Group Instructions, Safety Net Antibiotic Prescribing (SNAP) Group Instructions - Community Acquired Pneumonia (CAP), Community Acquired Pneumonia | Not applicable | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 2000 | 2025-09-09 | 2026-01-27 |
| ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT) Community Acquired Pneumonia (CAP) | Recruiting | Societa Italiana di Pneumologia | 1298 | 2025-08-11 | 2025-11-18 | |
| Local Antibiotic Delivery for Community Acquired Pneumonia Levofloxacin, Placebo - Community Acquired Pneumonia (CAP) | Phase 2 / Phase 3 | Not yet recruiting | Copenhagen Respiratory Research | 36 | 2025-03-04 | 2025-03-10 |
| Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure Acute Hypoxemic Respiratory Failure, Non Invasive Ventilation (NIV) | Active not recruiting | Hospital Universitari de Bellvitge | 500 | 2025-03-01 | 2026-01-16 | |
| Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support - Community Acquired Pneumonia (CAP), Sinusitis | Active not recruiting | Children's Hospital of Philadelphia | 420 | 2025-02-18 | 2026-04-14 | |
| Chest Radiography Versus Ultra-Low-Dose Chest Computed Tomography in Adults in the Emergency Department ULDCT - Community Acquired Pneumonia (CAP) | Recruiting | University of Southern Denmark | 66 | 2025-01-29 | 2026-10-13 | |
| Clinical Characteristics and Outcome of Patients With Community Acquired Pneumonia Community Acquired Pneumonia (CAP) | Not yet recruiting | Sohag University | 100 | 2024-12-15 | 2024-12-04 | |
| Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d, Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d - Respiratory Infection (for Example, Pneumonia, Bronchitis), Respiratory Infection Virus | Not applicable | Completed | University Hospital Schleswig-Holstein | 28 | 2024-04-20 | 2025-09-05 |
| Pneumonia Pathogens' Virulence Factors, Patient Inflammatory Markers, and Their Associations With Outcomes Inflammatory Biomarker Evaluation - Community Acquired Pneumonia (CAP), Hospital Acquired Pneumonia | Enrolling by invitation | Ruta Nutautiene | 300 | 2024-04-02 | 2025-06-08 | |
| Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Colombian Adults Community Acquired Pneumonia (CAP), Pneumococcal Pneumonia | Completed | Universidad de la Sabana | 688 | 2022-06-28 | 2026-01-21 | |
| Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE) RESPIRE score - Pneumonia, Pneumonia - Bacterial | Completed | Azienda Ospedaliero-Universitaria Careggi | 300 | 2022-01-01 | 2026-02-23 | |
| PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older Urine sample collection, Saliva collection - Community Acquired Pneumonia (CAP) | Completed | Pfizer | 1821 | 2021-03-12 | 2025-06-11 | |
| Lower Respiratory Tract Infections Managed in Primary Care in France Lower Respiratory Tract Infections, Community Acquired Pneumonia (CAP) | Completed | Hôpital Raymond Poincaré | 230066 | 2015-01-01 | 2026-02-18 | |
| Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections Community Acquired Pneumonia (CAP), Complicated Skin and Skin Structures Infections (cSSSI) | Completed | AstraZeneca | 4035 | 2011-03-01 | 2012-09-07 | |
| The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP) Azithromycin - Community Acquired Pneumonia (CAP) | Phase 3 | Completed | Pfizer | 102 | 2009-02-01 | 2011-05-19 |
Showing 20 of 21. Sign in to see all of them.
Community-Acquired Pneumonia (21) · Pneumonia (6) · Bronchitis (2) · Emergencies (2) · Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Colitis (1) · Community-Acquired Infections (1) · Healthcare-Associated Pneumonia (1) · Inflammation (1) · Inflammatory Bowel Diseases (1) · Influenza, Human (1) · Otitis Media (1) · Plaque, Atherosclerotic (1) · Pneumonia, Bacterial (1)
Infections (21) · Respiratory Tract Diseases (21) · Community-Acquired Infections (20) · Respiratory Tract Infections (20) · Pneumonia (15) · Lung Diseases (10) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Disease Attributes (5) · Bronchial Diseases (3) · Lung Diseases, Obstructive (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Chronic Disease (2) · Colonic Diseases (1)
Azithromycin (1) · Hydrocortisone (1) · Levofloxacin (1) · Methylprednisolone (1) · Pharmaceutical Preparations (1) · eicosapentaenoic acid ethyl ester (1) · telithromycin (1)
Copenhagen Respiratory Research (2) · Pfizer (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · AstraZeneca (1) · Azienda Ospedaliero-Universitaria Careggi (1) · Capital Medical University (1) · Children's Hospital of Philadelphia (1) · Hospital Universitari de Bellvitge (1) · Hôpital Raymond Poincaré (1) · Op-T LLC (1) · Ottawa Heart Institute Research Corporation (1) · Ruta Nutautiene (1) · Sanofi (1) · Societa Italiana di Pneumologia (1) · Sohag University (1)
United States (4) · Italy (3) · Spain (3) · Denmark (2) · Germany (2) · Belgium (1) · Canada (1) · China (1) · Colombia (1) · France (1) · Greece (1) · Japan (1) · Lithuania (1) · Netherlands (1) · Portugal (1)
Astra Vitkauskiene, prof. dr., MD, PhD (1) · Bin Cao, M.D. (1) · Binghuai Lu, M.D. (1) · Cristian C Serrano, MD, cPhD (1) · Francesco B.A. Blasi, MD (1) · Herbert B Slade, MD FAAAAI (1) · Jan Heyckendorf, Prof. Dr. (1) · Jens-Ulrik S. Jensen, Professor, MD, phD (1) · Julia Szymczak, PhD (1) · Kevin Boczar, MD (1) · Louis Bell, MD (1) · Luis F Reyes, MD,PhD, MsC (1) · Margaret Mississian (1)
PMID 23586347, PMID 24450444, PMID 24477328, PMID 25879713, PMID 26356705, PMID 31863551, PMID 32634800, PMID 32919458, PMID 33024653, PMID 41781043, PMID 42238377